Speak of lousy timing. After receiving a knighthood from the queen at the end of 2011, GSK CEO Andrew Witty was on a roll. The chair of GlaxoSmithKline’s compensation committee had pointed out that compared to his peers, Witty was being underpaid at £5.7 million ($8.84 million). It was concluded there is ”a significant competitiveness gap...




